Selectivity and Safety of VIP943: A Novel CD123-Targeting Antibody-Drug Conjugate (ADC) Using a Proprietary Linker and Payload Class

被引：2
|
作者：
Stelte-Ludwig, Beatrix [1 ]
Schomber, Tibor [1 ]
Izumi, Raquel [2 ]
Wong, Harvey [2 ]
Frigault, Melanie M. [2 ]
Rebstock, Anne-Sophie [1 ]
Ludwig, Sebastian [1 ]
Mithal, Arushi [2 ]
Johnson, Amy J. [2 ]
Hamdy, Ahmed [2 ]
机构：
[1] Vincerx Pharma GmbH, Monheim, Germany
[2] Vincerx Pharma, Palo Alto, CA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-182260
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 36 条
  • [31] Objective responses in a phase I dose-escalation study of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in patients with relapsed or refractory Hodgkin lymphoma
    Younes, A.
    Forero-Torres, A.
    Bartlett, N. L.
    Leonard, J. P.
    Rege, B.
    Kennedy, D. A.
    Lorenz, J. M.
    Sievers, E. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [32] Objective responses in a phase I dose-escalation study of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in patients with relapsed or refractory Hodgkin lymphoma
    Younes, A.
    Forero-Torres, A.
    Bartlett, N. L.
    Leonard, J. P.
    Rege, B.
    Kennedy, D. A.
    Lorenz, J. M.
    Sievers, E. L.
    ANNALS OF ONCOLOGY, 2008, 19 : 129 - 129
  • [33] Preclinical efficacy and safety of M9140, a novel antibody-drug conjugate (ADC) with topoisomerase 1 (TOP1) inhibitor payload targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)-expressing colorectal tumors
    Raab-Westphal, Sabine
    Hart, Felix
    Sloot, Willem
    Shan, Min
    Rasche, Nicolas
    Amendt, Christiane
    Anderl, Jan
    CANCER RESEARCH, 2024, 84 (06)
  • [34] INITIAL RESULTS FROM A FIRST-IN-HUMAN STUDY OF IMGN779, A CD33-TARGETING ANTIBODY-DRUG CONJUGATE (ADC) WITH NOVEL DNA ALKYLATING ACTIVITY, IN PATIENTS WITH RELAPSED OR REFRACTORY AML
    Cortes, J.
    DeAngelo, D.
    Wang, E.
    Arana-Yi, C.
    Zweidler-McKay, P.
    Munteanu, M.
    Andreu-Vieyra, C.
    Erba, H.
    Blum, W.
    Traer, E.
    HAEMATOLOGICA, 2017, 102 : 217 - 218
  • [35] Complete remissions with weekly dosing of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in a phase I dose-escalation study in patients with relapsed or refractory Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL)
    Bartlett, N.
    Forero-Torres, A.
    Rosenblatt, J.
    Fanale, M.
    Horning, S. J.
    Thompson, S.
    Sievers, E. L.
    Kennedy, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [36] Phase I expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC): Preliminary efficacy, safety, and biomarker results in patients with previously treated metastatic ovarian cancer (OC) or non-small cell lung cancer (NSCLC).
    Richardson, Debra L.
    Barve, Minal A.
    Strauss, James Fredric
    Ulahannan, Susanna Varkey
    Moore, Kathleen N.
    Hamilton, Erika Paige
    Johnson, Melissa Lynne
    Papadopoulos, Kyriakos P.
    Zarwan, Corrine
    Anderson, Charles K.
    Buscema, Joseph
    Doroshow, Deborah Blythe
    Edenfield, William Jeffery
    Matulonis, Ursula A.
    Burns, Timothy F.
    Huebner, Dirk
    Jansen, Valerie Malyvanh
    Mosher, Rebecca
    Jarlenski, Donna
    Tolcher, Anthony W.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
1234